Compare Abeona Therapeutics Inc (ABEO) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Intuitive Surgical, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Intuitive Surgical, Inc. trades at $418.93 (market cap $151.33B). The key difference: Intuitive Surgical, Inc. is far larger — about 405.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | ISRG | |
|---|---|---|
Market Cap | $373.32M | $151.33B |
Sector | Health | Health |
52-Week High | $7.23 | $592.85 |
52-Week Low | $4.17 | $397.68 |
Enterprise Value | $228.22M | $146.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Intuitive Surgical (ISRG) trades at $427.30, up 0.3% on the day, with a bullish technical outlook supported by moving averages and strong support at $422. The company reported robust Q1 2026 earnings of $2.50 per share, beating estimates, and has consistently exceeded expectations. Revenue grew to $10.06 billion in 2025, with a net income margin of 28.15%, though valuation multiples remain elevated with a P/E of 52.59.
The outlook is positive, driven by procedure growth guidance of 13.5-15.5% for 2026 and analyst consensus targeting $565.20. Risks include premium valuation sensitivity and reimbursement challenges in new markets like appendectomy. Institutional sentiment is bullish, with 69% of analysts rating it a buy, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
